Pilot study to compare pain therapy of donor site pain of iliac bone crest harvesting: Comparison between systemic pain therapy, local application of Ropivacain and Transversus-Abdominis-Plane-catheter

Pilot study to compare pain therapy of donor site pain of iliac bone crest harvesting: Comparison between systemic pain therapy, local application of Ropivacain and Transversus-Abdominis-Plane-catheter - STHBK

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00011058

Enrollment

Registered

2016-09-29

Start date

2017-02-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Other chronic pain R52.2

Interventions

Group 1: Systemic pain therapy: 90mg Arcoxia (Etoricoxib) once daily, taken orally, 50mg Tapentadol retard (Tapentadol) twice daily, taken orally, 40mg Pantozol (Pantoprazol) once daily, taken orally

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients (ASA I-III), which will be undergoing surgery with the need of anterior iliac bone crest harvesting

Exclusion criteria

Exclusion criteria: Rheumatic diseases, chronic pain of lumbar spine, Kox osteoarthritis, knee or hip prosthesis, earlier iliac bone crest harvesting, intolerance of local anaesthetics or other pain killers, abuse of opioids, chronic intake of pain killers, psychiatric diseases, infections of the abdominal wall, adiposity per magna (BMI= 40)

Design outcomes

Primary

Measure	Time frame
Differences in the intensity of pain between the patients with systemic pain therapy und the patients with Transversus-Abdominis-Plane-catheter; a) postoperative day 0-5: questionnaire; b) 6 weeks: postoperative: telephone interview; c) 3 months postoperative: telephone interview	—

Secondary

Measure	Time frame
Possible differences in the intensity of pain between the patients with the adjuvant pain therapies local application of Ropivacain or Transversus-Abdominis-Plane-catheter; a) postoperative day 0-5: questionnaire; b) 6 weeks postoperative: telephone interview; c) 3 months postoperative: telephone interview	—

Countries

Germany

Contacts

Public ContactMatthias Janda

Universitätsklinikum Rostock

matthias.janda@uni-rostock.de+493814946401

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026